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The TNF blockade therapy is currently a well-
established treatment option for a variety of autoim-
mune diseases such as rheumatoid arthritis (RA), pso-
riasis or Crohn's disease, given the proinflammatory 
role of TNF in the course of these diseases. Importantly, 
TNF neutralization is also used for the treatment of 
corticosteroid-refractory immune-related adverse 
events (irAEs) induced by the combined anti-PD-1 and 
anti-CTLA-4 immunotherapy. The manifestation of 
these toxicities is an important limiting factor for the 
successful implementation of the inhibitory checkpoint 
blockade therapy (ICB), restraining its anti-tumor effi-
cacy. In our recent study (Perez-Ruiz et al., Nature 
569(7756): 428-432.), we analyzed the potential impact 
of prophylactic TNF neutralization therapy in the anti-
PD1/CTLA-4 efficacy. Through several mouse models, 
we demonstrated that TNF neutralization ameliorated 
ICB-exacerbated colitis in addition to improving ICB-
dependent anti-tumor efficacy. Similar results were 
obtained after prophylactic TNF blockade in graft vs 
host xenografted mouse models with human immune 
cells, which showed a reduction in colitis and hepatitis. 
Importantly, there was a preservation of the immuno-
therapeutic control of xenografted tumors after ICB 
treatment. Moreover, TNF and TNF-dependent gene 
expression is upregulated in the colon mucosa from 
patients affected by colitis as a side effect of ipili-
mumab and nivolumab. Our results, thus, provide evi-
dence of the successful combination of prophylactic 
TNF neutralization with ICB therapy strategy to amelio-
rate toxicities, while keeping or even enhancing anti-
tumor efficacy. The prophylactic TNF blockade strategy 
is clinically feasible since excellent TNF inhibitors have 
been approved for the treatment of autoimmunity and 
are used for the immune-related serious adverse 
events in immunotherapy. 
 
Inhibitory checkpoint blockade (ICB) immunotherapy has 
produced very significant advances in the fight against can-
cer (Figure 1). The synergistic combination of PD-1 and 
CTLA-4 blockade therapy has been successfully used 
against a variety of tumors such as melanoma, renal cell 
carcinoma, or non-small-cell lung cancer with reportedly 
improved results when compared to single ICB therapy 
(Figure 1A-C). Unfortunately, the appearance of serious 
immune-related adverse events (irAEs) has hindered the 
overall anti-tumor response of these therapies by forcing a 
reduction of the dose or, in over 30% of patients, discon-
tinuation of the treatment (Figure 1C). The course of action 
towards these irAEs consist of steroids treatment followed 
by transient or permanent treatment discontinuation and 
TNF blockade therapy is routinely used when there is no 
response to steroids. By using tumor-transplanted mouse 
models and xenograft mouse models, we have demon-
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starting the dual anti-PD1 and anti-CTLA-4 therapy pre-
vents irAEs, while maintaining or even enhancing to some 
extent the therapeutic efficacy of combined ICB therapy 
(Figure 1D). 
The role of the TNF in the induction of ICB-mediated 
irAEs was proven in an autoimmune colitis mouse model 
that involved the induction of inflammatory bowel disease 
by dextran sulfate sodium (DSS). In this model, ICB therapy 
worsened the DSS-elicited autoimmune colitis with marked 
thickening of the intestinal wall and immune cell infiltra-
tion into the colon mucosa, signs that were prevented 
when TNF was neutralized by anti-TNF antibodies or 
etanercept. Importantly, the blockade of TNF resulted in an 
improvement of tumor survival in DSS-treated tumor-
bearing mice after ICB therapy, unlike IL-6 neutralization, 
which harmed rather than improved ICB-enhanced anti-
tumor responses. In the absence of DSS-induced colitis, ICB 
efficacy was retained when anti-TNF or etanercept was co-
administered. 
The effectiveness of prophylactic TNF neutralization 
treatment in ICB therapy was linked to a higher abundance 
of infiltrated antigen-specific CD8+ T cells in the tumor mi-
FIGURE 1: Reducing the toxicity of cancer immunotherapy. (A) The presence on activated lymphocytes of the inhibitory receptors PD-1, 
which binds to PD-L1, and CTLA-4, which binds to the costimulatory molecules CD80 and CD86, causes immune cell dysfunction facilitat-
ing tumor evasion. (B) The introduction of inhibitory blockade therapy that prevents PD-1/PD-L1 or CTLA-4/CD86-CD80 interactions by 
monoclonal antibody therapy has shown to improve CD8 T cell cytotoxic function and thus has been successfully implemented in a varie-
ty of tumors such as melanoma, with little toxicity. (C) Dual therapy that combines anti-PD-1 and anti-CTLA-4 has a more effective anti-
tumor response when compared to single therapy, but, at the cost of the increase in the frequency of immune-related adverse events, 
which induces tissue damage, being TNF an important mediator of this effect. (D) The administration of dual ICB therapy in combination 
with prophylactic TNF neutralization is able to palliate the treatment-related toxicity side effects while becoming more efficacious to-
wards the anti-tumor response by limiting the activation induced cell death (AICD) on the lymphocytes. 
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croenvironment and tumor-draining lymph nodes (dLN) 
with the presence of gp70- and OVA-positive CD8+ T cells in 
MC38 and B16-OVA mouse models, respectively. Pheno-
typical analysis of intratumoral antigen-specific CD8+ T cells 
using a non-competing monoclonal antibody against PD-1 
showed that these cells had a lower surface expression of 
this surface marker when mice received ICB therapy. Such 
downregulation of PD1 was also deadly observed when 
anti-TNF or etanercept was used. Interestingly, high levels 
of PD-1 have been correlated, along with other markers, 
with an exhaustion phenotype that it is characterized by 
functional impairment in CD8 T cells. These results raised 
the possibility that TNF-dependent ICB improved efficacy 
could be the result of a reduction in the proportion of anti-
gen-specific CD8+ T cells that display an exhaustion pheno-
type. However, when the expression of various exhaustion 
markers (Tim3, Lag3, CTLA-4, BTLA, CD160, and 2B4) was 
analyzed, no differences were observed in any of them 
when compared to DSS-control treated antigen-specific 
CD8+ T cells independently of TNF neutralization. These 
data can be explained by a selective expansion of PD1-/low 
CD8+ T cells as a result of ICB treatment. 
Another important difference observed was a reduc-
tion in the proportion of cell death within total and anti-
gen-specific CD8+ T cells in the tumor microenvironment 
and dLN of mice as a result of systemic TNF neutralization, 
suggesting an attenuation of the activation-induced cell 
death (AICD). A similar reduction in apoptosis was obtained 
when T cell-receptor (TCR)-transgenic mouse CD8+ OT-I and 
Pmel-1 cells were activated in vitro with their correspond-
ing peptides and co-cultured with anti-PD1/CTLA-4 in the 
presence of anti-TNF or etanercept in comparison with ICB 
treatment alone. Furthermore, the induction of AICD by 
the in vitro activation of human CD8+ T cells from healthy 
donors with anti-CD3/CD28 was reduced by infliximab or 
etanercept treatment. Thus, these data suggest that the 
mechanisms of action for TNF blockade seem to operate 
through a reduction of ICB-induced AICD. This immune 
phenomenon has been recently reported to limit the anti-
tumor efficacy of the anti-PD-1/anti-CTLA-4 combined 
treatment in a low tumor burden setting characterized by 
tumor infiltration with partially exhausted T lymphocytes. 
In this report, IFN-γ was identified as a critical mediator of 
AICD, but IFN-γ blockade will likely affect the antitumor 
activity of T lymphocytes. Our data map the route of a clin-
ically feasible strategy to promote the antitumor immune 
responses elicited by combined ICB, while preventing auto-
immune reactions 
To validate the results obtained in the mouse models 
and further probe the connection of TNF with ICB efficacy, 
we next performed an mRNA analysis of immune-related 
genes from biopsies of i) healthy mucosal tissue in cancer 
patients, ii) colon tissue from patients diagnosed with coli-
tis after nivolumab and/or ipilimumab administration or iii) 
colon tissue from patients diagnosed with ulcerative colitis. 
In both ICB-mediated colitis and ulcerative colitis, TNF 
mRNA was significantly upregulated when compared to 
colon healthy tissue samples. In addition, a gene signature 
of TNF active tray was present in the mucosa of these pa-
tients. Using a xenograft-versus-host model disease, in 
which human peripheral blood mononuclear cells (PBMCs) 
were injected intravenously into Rag2-/-IL2rg-/- mice, we 
observed that ipilimumab and nivolumab treatment exac-
erbated immune-mediated colitis with an increase of 
weight loss and inflammation of the large intestine signi-
fied by the thickness of the intestinal wall. As expected 
from results obtained in mouse models, this effect was 
minimized by the co-treatment with etanercept. Moreover, 
in the presence of the human tumor cell line HT29 in the 
xenograft-versus-host model disease, etanercept treat-
ment retained the ICB-mediated anti-tumor efficacy and 
decreased the level of alanine transaminase and aspartate 
transaminase in serum as well as reduced the thickness of 
the intestinal wall, all of which suggest a reduction in hepa-
titis and colitis that result from the xenograft from the host 
reaction. These results recapitulated the data obtained in 
mouse models and provide evidence for the potential ben-




Despite the enormous efforts made to improve anti-tumor 
responses by ICB therapy, the manifestation of treatment-
related toxicities has become a critical limiting factor for its 
applicability. Thus, efforts towards improving tolerability 
are required. Taking into consideration our findings, the 
administration of TNF neutralization agents prophylactical-
ly or concomitantly with ICB therapy was capable of resolv-
ing these shortcomings for ICB immunotherapy, while re-
taining its anti-tumor efficacy, presenting a strategy that 
allows for a separation between efficacy and toxicity (Fig-
ure 1). Moreover, with this approach, a sustained and/or 
higher dose regimen of ICB compounds would be tolerated, 
which could strengthen its anticarcinogenic potential. Cur-
rently, a phase I investigator-initiated trial 
(https://clinicaltrials.gov; NCT03293784) is undergoing to 
evaluate the safety of the proposed approach. Sufficiently 
powered randomized clinical trials measuring overall re-
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